Buradasınız

SWELLING CONTROLLED DRUG DELIVERY CONTAINING THE EXTRACT OFTRIGONELLA FOENUM : A NOVEL APPROACH FOR ANTI-DIABETIC TREATMENT

Journal Name:

Publication Year:

Abstract (2. Language): 
The anti-diabetic properties of Fenugreek (Trigonella foenum) seeds are due to 4-hydroxyisoleucine, a free amino acid. This compound stimulates insulin secretion and this extract is formulated into microbeads and controlled release can decrease the dosing times. This research article includes formulation and evaluation of a controlled drug delivery (CDD) i.e., swelling controlled microbeads containing the extracts of Trigonella foenum. The in-vitro drug release study reveals that the batch containing sodium alginate and HPMC (9:1) possesses better drug release at 7.4 pH in a sustained manner with better entrapment efficiency, degree of swelling, physical appearance including particle size and shape comparatively. Further pharmacological screening by Oral Glucose Tolerance Test method on animal models confirmed the sustained drug release and anti-hyperglycaemic activity. By developing this swelling controlled drug delivery system, a novel approach was made to prove the effect of 4-hydroxy isoleucine in Trigonella foenum seed extract as an anti-diabetic agent and a measure to validate the traditional use of fenugreek seed in anti-diabetic treatment.
695
697

REFERENCES

References: 

1. A. Gupta, R. Gupta, B. Lal. Effect of Trigonella
foenum-graecum (fenugreek) seeds on glycaemic
control and insulin resistance in type 2 diabetes
mellitus: a double blind placebo controlled study, J
Assoc Physicians India 49: 1057-1061 (2001).
2. K. A. Wadkar C. S. Magdum, S. S. Patil and N. S.
Naikwade. Anti-Diabetic Potential and Indian
Medicinal Plants, Journal of Herbal Medicine and
Toxicology 2 (1): 45-50 (2008).
3. C. Renuka, N. Ramesh and K. Saravanan. Evaluation
of the anti-diabetic effect of Trigonella foenumgraecum
seed powder on alloxan induced diabetic
albino rats, International Journal of PharmTech
Research 1(4): 1580-1584 (2009).
S. No. Group/Dose (Per kg BW) Blood glucose concentration(mg/dL)
0 min 60min 120min 240min 360min
1. Untreated Control (normal saline) 83.8±2.02 113±1.35 94.2±1.17 105±1.12 81.5±0.76
2. Diabetic control
(2gm/kg BW)
282±0.946aaa 265±1.63aaa 209±1.46aaa 192±0.882aaa 194±1.05aaa
3. Isoleucine
(10.5mg/kgBW)
282±1.15 178±1.53bbb 93±1.63bbb 124±1.30bbb 185±2.12bbb
4. Glimepiride(0.018mg/kg BW) 285±1.69 211±1.76bbb 161±1.71bbb 63±2.25bbb 48.3±2.26bbb
5. Extract(90 mg/kg BW) 278±2.14 183±1.50bbb 109±1.42bbb 75±1.69bbb 183±1.64bbb
6. Formulation (214 mg/250 gm BW) 278±3.32 150±2.54###bbb 135±2.14###bbb 78±1.46bbb 72.3±2.11###bbb
Nilani et al., ARPB, 2014; Vol 4 (II) ISSN 2250-0774
(RESEARCH ARTICLE)
697 | P a g e w w w . a r p b . i n f o
4. P. Petit, C. Broca, M. Manteghetti, Y. Baissac, J.
Fernandez-Alvarez. 4-Hydroxyisoleucine:
experimental evidence of its insulinotropic and
antidiabetic properties, Am J Physiol Endocrinol
Metab 277: E617-E623 (1999).
5. S. A. Shah, I. S. Rathod, D. Kanakia. Colorimetry
method for estimation of glycine, alanine and
isoleucine, Indian Journal of pharmaceutical
sciences 69 (3): 462-464 (2007).
6. T. Ostberg, E. Marie, L. Christina Graffner. Calcium
alginate matrices for oral multiple unit
administration: IV. Release characteristics in
different media, Int. J. Pharm 112: 241-248 (1994).
7. Ling Zhao, Yu-meng Wei, Yu Yu and Wenwu
Zheng. Polymer blends used to prepare
nifedipine loaded hollow microspheres for a
floating-type oral drug delivery system: In
vitro evaluation, Archives of Pharmacal
Research 33 (3): 443-450 (2010).
8. S. Srinivasan, B. Karundevi. Comparative
evaluation of hypoglycemic activity of two
medicicnal plants in alloxan diabetic rats,
International Journal of Pharmacology 1(3):
267-276 (2005).

Thank you for copying data from http://www.arastirmax.com